Transition to Metastatic State: Lung Cancer, Pancreatic Cancer and Brain Metastasis

项目总结(总体单位) 转移是肿瘤动态的、复杂的、全身性的病理生理过程。传播 原发肿瘤部位以外的癌细胞是导致大多数癌症死亡的原因，也是 癌症复杂进化动态的公开表达。与错综复杂的 发展和免疫的过程，从局部浸润性癌症到转移性癌症的转变 这是一个重大的科学障碍。最新的技术和计算进步，由我们的 团队能够对多个组织进行动态、多维、多平面的分析。应用这些 美国最致命的癌症：肺癌、胰腺癌和中枢神经系统转移癌的进展 我们将生成一个具有前所未有的时空分辨率的人体组织图谱。这 多学科的努力始于无与伦比的人体组织和临床数据阵列，由 我们的生化单位团队。这些高质量的生物标本将从肺癌中获得， 从手术切除、活检或尸检获得的胰腺癌和中枢神经系统转移。数据 分析小组将对这些标本进行多维分析，包括 大量DNA测序，单细胞和单核RNA测序，以及建筑- 敏感性分析包括MIBI(蛋白质)和MerFish(RNA)技术。由革命者推动 计算生物学家和系统生物学家将对这些数据集进行整合和演示 由特定股编写，目的是编制有价值的权威性人类肿瘤地图集 整个癌症研究界。

PROJECT SUMMARY (Overall Unit) Metastasis embodies the dynamic, complex, whole-organism pathophysiology of cancer. Spread of cancer cells beyond the primary tumor site is the cause of the majority of cancer deaths and the most overt expression of cancer's complex evolutionary dynamics. Intimately related to the intricate processes of development and immunity, the transition from locally invasive to metastatic cancer poses a major scientific hurdle. Recent technological and computational advancements, pioneered by our team enable dynamic, multi-dimensional, multi-planar analysis of multiple tissues. Applying these advances to the most lethal cancers in the US: Lung Cancer, Pancreatic Cancer and CNS metastases, we will generate a Human Tissue Atlas with unprecedented spatial-temporal resolution. This multidisciplinary effort begins with an unparalleled array of human tissues and clinical data acquired by our Biospecimen Unit team. These high-quality biospecimens will be obtained from lung cancer, pancreatic cancer and CNS metastases obtained from surgical resections, biopsy or autopsy. The Data Analysis Unit will then subject these specimens will be subjected to multi-dimensional analysis including bulk DNA sequencing, single cell and single nuclear RNA sequencing, as well as architecturally- sensitive analyses including MIBI (protein) and MERFISH (RNA) technologies. Driven by revolutionary computational and systems biologists, integration and presentation of these datasets will be undertaken by the Characterization Unit, with the goal of generating authoritative human tumor atlases of value to the entire cancer research community.